Massachusetts-based, IDRx, a biopharmaceutical company at the clinical stage recently raised $120 million led by RA Capital Management in a Series B.
Blackstone Multi-Asset Investing and Commodore Capital actively backed the round. Some investors such as US healthcare-focused funds and Rock Springs Capital also participated in the round.
Casdin Capital, Andreessen Horowitz (a16z) Bio + Health, Forge Life Science Partners, Nextech Invest Ltd., and strategic partner Merck KGaA have also participated in the round.
Massachusetts-Based IDRx Raised $120M Series
CEO IDRx, Tim Clackson said that the funds raised will help us to expand operations.
IDRx is a biopharmaceutical company that helps medical institutes with cancer care. Their intelligent and precise therapies are designed to transform the medical industry.
Moreover, the IDRX-42 program is designed to provide drug mutation and key genetic drivers. Also, IDRx invest in Phase 1/1b StrateGIST 1 study.
Also Read: Terrantic Raised $3.5M Seed By Supply Change Capital